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Edoardo Lanino,1 Roberto Rondelli,2 Franco Locatelli,3 Chiara Messina,4 Andrea Pession,2
Adriana Balduzzi,5 Claudio Favre,6 Stella Santarone,7 Marco Rabusin,8 Simona Pollichieni,9
Simone Cesaro,4 Giorgio Dini,1 Franca Fagioli for the AIEOP-HSCT Group10We carried out a randomized, multicenter study comparing the inception of cyclosporine- A (CsA) on day –7
to conventional CsA (on day –1) to evaluate the influence of this modification on graft-versus-host disease
(GVHD), treatment-related mortality (TRM), relapse rate (RR), and event-free survival (EFS) in children with
hematologic malignancies given unrelated donor (UD) hematopoietic stem cell transplantation (HSCT). Be-
tween 1997 and 2002, 152 children transplanted for acute leukemia (102), myelodysplastic syndromes (23),
chronic myelogenous leukemia (20), and non-Hodgkin lymphoma (7) were enrolled in the study and random-
ized to receive either early CsA (group 1, N5 72) or conventional CsA (group 2, N5 80), after stratification
according to HLA compatibility and disease phase. The cumulative incidence of both grade II-IV and grade II-
IV acute GVHD (aGVHD), as well as of chronic GVHD (cGVHD), did not differ between the 2 groups. No
significant differences were observed also with regard to TRM and RR. The 8-year Kaplan-Meier estimates of
EFS were 56% in group 1, and 46% in group 2 (P 5 NS). In the Cox model, advanced disease phase, male
recipient, older donor, and occurrence of grade III-IV aGVHD predicted inferior overall EFS. These data in-
dicate that early inception of CsA does not improve posttransplantation outcome of children with hemato-
logic malignancies given UD-HSCT.
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Hematopoietic stem cell transplantation (HSCT)
from an HLA-identical sibling has become an estab-
lished treatment for children with hematologic malig-
nancies, bone marrow failure syndromes, and various
inborn errors [1-3]. Because\1 of 4 patients has an1U.O. Ematologia ed Oncologia Pediatrica, Istituto G.
i, Genova, Italy; 2Dipartimento Scienze Pediatriche
he e Chirurgiche, Ospedale S. Orsola Malpighi, Univer-
Bologna, Italy; 3Oncoematologia Pediatrica, Fondazione
S Policlinico S. Matteo, Universita` di Pavia, Pavia, Italy;
ca di Oncoematologia Pediatrica, Universita` di Padova,
a, Italy; 5Clinica Pediatrica, Universita` di Milano-
ca, Ospedale S. Gerardo, Monza, Italy; 6Clinica Pedia-
Universita` di Pisa, Pisa, Italy; 7Dipartimento di Ematolo-
spedale Civile di Pescara, Pescara, Italy; 8Clinica
trica, Universita` di Trieste, Trieste, Italy; 9Registro Ital-
onatori di Midollo Osseo, Ospedali Galliera, Genova,HLA-matched sibling, the use of unrelated donors
(UD) has significantly increased over the last few years.
We recently reported that the outcomeof childrenwith
acute leukemia given UD-HSCT has significantly
improved over time, becoming comparable to that of
patients transplanted from a compatible relative [4].
The main factors that have significantly contributedItaly; and 10Oncoematologia Pediatrica, Ospedale Infantile Re-
gina Margherita, Torino, Italy.
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cause of a more precise characterization of HLA loci
[5], and refinements in both prophylaxis and treatment
of graft-versus-host disease (GVHD). Despite this im-
provement, however, GVHD and transplantation-
related toxicity are stillmajor contributors to both early
and late morbidity and mortality in UD-HSCT. Usu-
ally, in Italy, GVHD prophylaxis for children with ma-
lignancies given UD-HSCT includes serotherapy
(namely, antilymphocyte globulin (ALG) or antithy-
mocyte globulin [ATG]), cyclosporine-A (CsA) from
day –1, and short-course methotrexate (MTX) [6].
However, a single center study by Lamparelli et al.
[7], and a retrospective analysis fromour group [8], sug-
gested that early administration of CsA (from day 27
before HSCT) may improve outcome. This effect
was interpreted to be because of higher levels of the
drug at time of transplantation, resulting both in a re-
duction of the cytokine storm induced by the condi-
tioning regimen and in a blunted early activation of
donor T cells [9]. To test prospectively in a controlled
trial whether early inceptionofCsA can improve the re-
sults of UD-HSCT, the transplant subcommittee of
the Italian Association of Pediatric Hematology and
Oncology (AIEOP) designed a randomized study com-
paring early inception of CsA (ie, from day27, during
conditioning regimen) with conventional CsA (ie, from
day21). The primary endpoints of the study were the
incidence of acute and chronic GVHD (aGVHD,
cGVHD), treatment-related mortality (TRM), relapse
rate (RR), and event-free survival (EFS).Moreover, the
impact of other patient-, donor-, and transplantation-
related factors on TRM, RR, and EFS was assessed.PATIENTS AND METHODS
Between September 1997 and October 2002, 152
consecutive children 18 years or younger (median
age: 9 years), undergoing first HSCT from an UD
for hematologic malignancies in 9 HSCT centers affil-
iated to AIEOP, were enrolled in this prospective
study. UDs were identified through a network of na-
tional and international bone marrow donor registries,
as previously described [10].
The major endpoint of the study was to determine
whether the early inception of CsA could improve EFS
probability, compared to conventional CsA. Random-
ization by a 1:1 allocation ratio after stratification
according to HLA compatibility and disease phase,
as described below, was centralized at the Department
of Pediatrics, Ospedale Sant’Orsola, Bologna, by 1 of
the investigators (R.R.) who was not involved in the
clinical management of the patients.
To calculate the sample size, a 2-sided log-rank
test was used. To obtain a study significance level of
.05 and a study power of .80 and supposing an EFSprobability at 5 years of .60 for patients given early
CsA and .45 for the second arm of the study, 100 pa-
tients per arm with an accrual time of 5 years and an
overall study duration of 7 years were planned. To
monitor the results of the trial, interim analyses were
performed 3 years after the beginning of the study
and, subsequently, every year. It was decided that pa-
tient enrolment should be closed when the difference
in overall survival (OS) between the 2 arms reached
a P value of .05. The analysis was based on the inten-
tion-to-treat principle. At the fifth year, futility analy-
sis based on the EFS estimates observed in the 2 arms
indicated a low probability (\30% under the most ex-
treme hypothesis) that the study detected a significant
difference if the planned sample size (100 patients per
arm) was reached. Patient accrual was then stopped.
Histocompatibility for all donor-recipient pairs
was determined by serology for HLA-A and -B anti-
gens and high-resolution allelic technique for DRB1.
Pairs matched for HLA-A, -B, and -DRB1 were de-
fined as 6/6 matched loci, whereas pairs in which there
was incompatibility for a single HLA locus were de-
fined as 5/6 matched loci. Since 1998, high-resolution
molecular typings were performed to characterize
HLA class I loci as well, in 130 patients, but the result-
ing information was not considered for patient stratifi-
cation.
Patients with acute lymphoblastic leukemia (ALL)
in second complete remission (CR), acute myeloge-
nous leukemia (AML) or non-Hodgkin lymphoma
(NHL) in first CR, as well as children with low-blast
count myelodysplastic syndrome (ie, refractory cyto-
penia) or chronic myelogenous leukemia (CML) in
first chronic phase were assigned to the ‘‘low-risk ’’
group, whereas children with more advanced disease
were included in the ‘‘high-risk ’’ group. Patients
were randomized using a computer-generated random
list, and stratified according to HLA matching and
disease phase. The distribution was homogeneous
between the 2 groups (1 and 2) for patient-, donor-,
and transplantation-related characteristics, as shown
in Table 1.
The source of progenitor cellswas bonemarrow for
all transplants. The parents of all children gave written
informed consent and understood the experimental na-
ture the study, which was approved by the institutional
review board at each of the participating Institutions.
Pretransplantation preparative regimens were all
myeloablative and chosen according to institutional
protocols, on the basis of the underlying disease and
its phase, aswell as on the recipient’s age.Most children
with ALLorNHL received a preparative regimen con-
taining total body irradiation (TBI), associated with
thiotepa and cyclophosphamide (Cy) [4]. The majority
of children with AML and with myelodysplastic
syndromes (MDS) received a non-TBI containing reg-
imen, including busulphan (Bu), cyclophosphamide
Table 1. Characteristics of Patients According to the Arm of
Randomization
CsA 27 CsA 21
P ValueN 5 72 N 5 80
Percentage (47%) (53%)
Diagnosis
ALL 40 (56%) 39 (49%) NS#
AML 9 (12%) 14 (17%)
MDS 12 (17%) 11 (14%)
CML 6 (8%) 14 (17%)
Non-Hodgkin lymphoma 5 (7%) 2 (3%)
Disease phase
Early 53 (74%) 63 (79%)
Advanced 19 (26%) 17 (21%) NS#
Patient sex
Male 47 (65%) 47 (59%)
Female 25 (35%) 33 (41%) NS#
Patient age at dx (years)
Median 6 8
Range (0-15) (0-17) .038§
Patient age at HSCT (years)
Median 8 10
Range (1-18) (1-18) NS§
Dx-HSCT interval (months)
Median 27 24
Range (3-79) (3-80) NS§
HLA matching
A, B, DRB1 6/6 53 (74%) 63 (79%)
5/6 19 (26%) 17 (21%) NS#
Sex matching
Don F/Rec M 17 (24%) 18 (23%)
Other combinations 55 (76%) 62 (77%) NS#
Donor/recipient h-CMV serology
Neg/neg 18 (25%) 11 (14%)
Pos donor
and/or recipient
54 (75%) 69 (86%) NS#
Donor age (years)
Median 35 36
Range (20-54) (23-52) NS§
Conditioning regimen
TBI plus chemotherapy 47 (65%) 52 (65%)
Chemotherapy alone 25 (35%) 28 (35%) NS#
Nucleated cells
infused (108/kg)
Median 6.2 5.3
Range (1-25) (0.5-14) NS§
CsA27, indicates cyclosporine from day –7; CsA21 cyclosporine from
day –1; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leu-
kemia; MDS, myelodysplastic syndromes; CML, chronic myelogenous leu-
kemia; HSCT, hematopoietic stem cell transplantation; Don, donor; F,
female; Rec, recipient; M, male; Neg, negative; Pos, positive; TBI, total
body irradiation; h-CMV, human cytomegalovirus.
#indicates two-tailed Fisher’s exact test; dx, diagnosis.
§t-test
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CML received a preparative regimen containing TBI
and Cy, as previously reported [8].
aGVHD and cGVHD were diagnosed and graded
at each transplant Centre according to the Seattle
criteria [12,13]. Patients surviving .14 and 100 days
posttransplantation were evaluated for aGVHD and
cGVHD occurrence, respectively. Treatment of both
aGVHD and cGVHD, supportive therapy, as well as
prophylaxis and treatment of infections [14,15], were
administered according to protocols in use at each
participating Institution.The combination of CsA (3 mg/kg/day from day
21), short-course MTX (15 mg/m2 on day 11, 10
mg/m2 on days 13,16, and 111) and ATG (Thymo-
globuline, 3.75 mg/kg from day 24 to day 22) was
given to the 80 children randomized to standard
CsA. Before receiving the same GVHD prophylaxis,
the 72 children allocated to early CsA had also received
CsA 1mg/kg/day from day27 to day22. CsA was ini-
tially administered intravenously as a 2-hour infusion
every 12 hours; when patients were able to tolerate
oral intake, CsA was shifted to 6 mg/kg/day twice daily
by mouth.
Blood levels of CsA were monitored twice weekly
until day 129, once a week from day 30 to day 60
and every 2 weeks from day 60 to day 180 or according
to clinical requirements. CsA doses were not adjusted,
unless trough blood levels exceeded 300 ng/mL; in the
absence of GVHD, CsA was tapered by 20% to 25%
every month starting on day160 and then usually dis-
continued within the end of month 6.Statistical Analysis
Datawere analyzed as of February 15, 2008.All data
were stored in a central data base (AIEOP–BMTRegis-
try), and were analyzed at the AIEOPOperation Office
[16].
Demographic and clinical characteristics of the 2
groups of patients were compared using the 2-tailed
Fisher’s exact test for categoric variables (sex, disease,
conditioning regimens, HLAmatching, sexmatching),
as well as Wilcoxon’s rank sum test and the t-test for
continuous variables (age, time interval between diag-
nosis and HSCT, marrow cell dose) [17].
The primary endpoint of this study was to evaluate
the influence of early CsA onEFS, whereas the second-
ary endpoints were to investigate if this modification
had an impact on aGVHD and cGVHD incidence, as
well as on RR and TRM. Moreover, we evaluated the
impact of the following patient-, donor-, and trans-
plant-related factors on outcome: primary diagnosis,
disease phase, recipient sex, recipient age at diagnosis
and at HSCT, interval diagnosis-HSCT, donor age
and sex, donor-recipient pair HLA compatibility (6/6
loci matched versus 12locus mismatched), human
cytomegalovirus (h-CMV) serology, conditioning reg-
imen (TBI versus chemotherapy), number of nucleated
cells infused, aGVHD, and cGVHD occurrence.
Patients were censored at time of relapse or death or
last follow-up, whichever occurred first [18,19].
The probabilities of OS and EFS were estimated by
the Kaplan-Meier method and expressed as percentages
and standard error (SE) [20], whereas RR and TRM
were calculated as cumulative incidence curves, to adjust
the analysis for competing risks [21,22]. For aGVHD
and cGVHD, death and relapse were the competing
events. For relapse, nonrelapse mortality (NRM) was
Table 2. Causes of Death in the Study Population
Number of Patients
Random CsA 27 CSA 21
Cause of death
First
100 Days
after
HSCT
After
100 Days
from
HSCT
First
100 Days
after
HSCT
After
100 Days
from
HSCT
Acute GVHD 2 1 3
Chronic GVHD 2
Idiopatic pneumonia 4 2 2 2
Aspergillus pneumonia 1 1 2
h-CMV pneumonia 1 1 1
Fungal infections 1 1
Bacterial sepsis 3 2 1
VOD 1
MOF 1
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sented the competing event.
The significance of differences between EFS
curves was estimated by the log-rank test (Mantel-
Cox), whereas Gray’s test [23] was used to assess
differences in univariate analyses of RR and TRM.
All variables with a P value\.05 in univariate analysis
were included in a multivariate analysis on EFS, per-
formed using the Cox proportional hazard regression
model using a backward selection procedure, whereas
the proportional subdistribution hazard regression
model [24] was used to perform multivariate analyses
of RR and TRM.
Statistical analysis was performed using the STATA
package [25] and the R 2.5.0 software package [26].EBV PTLD 1 2 1
TTP 1
Total number of patients dead
for transplant-related causes
17 23
Disease progression 4 9 3 13
Total 11 19 17 22
HSCT indicates hematopoietic stem cell transplantion; GVHD, graft-
versus-host disease; h-CMV, human cytomegalovirus; VOD, veno-
occlusive disease; MOF, multiple organ failure; EBV-PTLD, Epstein-Barr
virus-related posttransplant lymphoproliferative disease; TTP, throm-
botic thrombocytopenic purpura.RESULTS
Themedian follow-up for survivors in the 2 groups
of patients given either early or standard CsA is 85
(range: 56-110) and 82 (range: 53-113)months, respec-
tively (P 5 NS). The median follow-up for deceased
patients in the 2 groups is 4 (range: 1-23) and 6 (range:
0-73) months, respectively (P5NS).
Engraftment and GVHD Occurrence
Eight patients died before engraftment. The
remaining 144 patients engrafted; no significant differ-
ence for neutrophil or platelet recovery was observed
between the 2 groups (data not shown). The 100-day
cumulative incidence of grade II-IV aGVHD in pa-
tients given either early or standard CsA was 57.1%
(SE 5.9) and 67.6% (SE 5.4), respectively (P 5 NS),
whereas the 100-day cumulative incidence of grade
III-IV aGVHD was 27.2% (SE 5.3) and 31.1% (SE
5.4), respectively (P 5 NS).
Fifty-five (47%) of the 118 patients at risk devel-
oped cGVHD, which was limited in 27 cases (23%)
and extensive in the remaining 28 (24%). The cumula-
tive incidence of cGVHD occurrence was 39.3%
(SE 6.6) and 55.4% (SE 6.5) for children given early
or standard CsA, respectively (P 5 NS). cGVHD
was never of de novo origin and, thus, a previous
occurrence of aGVHD was the only factor predicting
the occurrence of cGVHD. None of the other charac-
teristics we analyzed had any influence on the inci-
dence and severity of either aGVHD or cGVHD.
TRM
Forty (26%) children died of transplantation-
related causes at a median time of 3 months (range:
0-73) after transplantation. Details on the causes of
death are reported in Table 2.
The overall 100-day and 1-year cumulative inci-
dence of TRM for children given early CsA was 9.7%
(SE 3.4), and 24% (SE 4.7), whereas the 7-yearcumulative incidence of TRM was 23.6% (SE 5.0).
For patients allocated to standard CsA, the overall
100-day, 1-year, and 7-year cumulative incidence of
TRM was 17.5% (SE 4.2), 23.7% (SE 4.7), and
29.4% (SE 5.2), thus indicating that for none of the
three estimations there was any difference between
the two groups. In the univariate analysis, the following
characteristics were significantly associated with lower
100-day TRM: patient age\9 years (P 5 .024), nega-
tive donor/recipient HCMV serology (P5 .044), a nu-
cleated cell dose infused.4.8 108/kg (P5 .017), and
grade 0-II aGVHD (P\ .0001) (see also Table 3 for
details). All these variables lost their prognostic signif-
icance in the multivariate model (Table 4).Relapse
Relapse of the underlying disease occurred in 34
(22%) patients at a median time of 6 months (range:
1-69) after the allograft. The cumulative incidence of
relapse for children given early or standard CsA was
20.8% (SE 4.8) and 24.2% (SE 4.9), respectively
(P 5 NS) with no difference in the timing of relapse
between the 2 groups. The cumulative incidence of
relapse for children with ALL allocated in the 2 ran-
domization arms was 17.5% (SE 6.0) and 28.2% (SE
7.2), respectively (P 5 NS). Disease progression was
the direct cause of death in 29 cases. Details on tim-
ing of disease-related deaths are reported in Table 2.
Table 3. Univariate Analysis of Variables Potentially Influencing Event-Free Survival, Relapse Rate, and 12-Month Treatment-
Related Mortality
Variable EFS (95% CI) RR (95% CI) 12-Month TRM (95% CI)
Random CSA day 27 56% (43-66) 21% (13-33) 24% (16-36)
CSA day 21 46% (35-57) 24% (16-36) 24% (16-35)
P value NS§ NS# NS#
Disease phase Early 57% (47-66) 17% (11-25) 23% (17-32)
Advanced 31% (17-46) 41% (28-61) 25% (14-44)
P value 0.0004§ 0.0006# NS#
Patient sex Male 43% (33-53) 29% (21-40) 27% (19-37)
Female 64% (50-75) 12% (6-24) 19% (11-32)
P value 0.026§ 0.023# NS#
Patient age at HSCT (years) <9 53% (40-64) 29% (20-42) 16% (9-28)
$9 49% (38-59) 17% (11-27) 30% (21-41)
P value NS§ 0.044# 0.024#
Dx-HSCT interval (months) < 16 53% (40-63) 23% (15-34) 20% (13-31)
$ 16 49% (38-60) 22% (15-34) 27% (19-39)
P value NS§ NS# NS#
HLA matching A, B, DRB1 6/6 54% (44-63) 22% (16-31) 19% (14-29)
5/6 41% (24-56) 23% (13-43) 36% (23-56)
P value NS§ NS# NS#
Sex matching Don F/Rec M 46% (29-61) 29% (17-48) 26% (15-45)
Other combinations 52% (43-61) 21% (15-30) 23% (17-32)
P value NS§ NS# NS#
Donor/recipient CMV
serology
Neg/neg 54% (34-70) 36% (21-59) 10% (3-30)
Pos Don and/or Rec 50% (41-59) 20% (14-28) 26% (19-35)
P value NS§ NS# 0.044#
Donor age (years) <35 60% (48-71) 20% (13-32) 16% (10-28)
$35 43% (31-53) 24% (16-36) 30% (22-42)
P value 0.027§ NS# NS#
Conditioning regimen TBI plus chemotherapy 51% (41-61) 21% (14-30) 24% (17-35)
Chemotherapy alone 48% (34-61) 27% (17-42) 23% (14-38)
P value NS§ NS# NS#
Nucleated cells infused <4.8 50% (38-61) 15% (9-26) 31% (22-43)
(108/kg) $4.8 52% (40-62) 30% (21-42) 17% (10-28)
P value NS§ 0.012# 0.017#
A, B, 0 group matching Matched 49% (35-61) 25% (16-40) 25% (16-39)
Mismatched 54% (37-68) 24% (14-39) 22% (13-36)
P value NS§ NS# NS#
Acute GVHD grade 0-II 60% (50-69) 26% (19-37) 11% (6-19)
III-IV 32% (19-47) 13% (6-29) 50% (37-68)
P value 0.0012§ NS# 0.0000#
Chronic GVHD Absent 64% (51-74) 27% (18-40) 9% (4-20)
Present 66% (51-77) 19% (11-33) 9% (4-21)
P value NS§ NS# NS#
EFS indicates event-free survival; RR, relapse rate; TRM, treatment-related mortality; CI, confidence interval; CsA 27, cyclosporine from day –7;
CsA21 cyclosporine from day –1; HSCT, hematopoietic stem cell transplantation; Don, donor; F, female; Rec, recipient; M, male; CMV, cytomegalovirus;
Neg, negative; Pos, positive; TBI, total body irradiation.
§log-rank test.
#Gray’s test.
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predicted an increased risk of recurrence: advanced
disease phase (P 5 .0006), male sex (P 5 .023), age
\9 years (P 5 .044), and a number of nucleated cells
infused .4.8  108/kg (P 5 .018) (Table 3). In multi-
variate analysis, only advanced disease phase (P 5
.0032), and male sex (P 5 .019) remained significantly
correlated with an increased risk of relapse (also see
Table 4 for details).OS and EFS
Overall, 83 (55%) children are alive after HSCT,
and 78 of them (51% of the total) are disease free,
the 8-year Kaplan–Meier estimate of survival andEFS for the whole cohort of patients being 54.2%
(SE 4.1) and 50.9% (SE 4.1), respectively (see also
Figure 1); 8-year EFS was 55.6% (SE 5.9) and 46.3%
(SE 5.7) for patients given early or standard CsA, re-
spectively (P 5 NS, see also Figure 2). Noteworthy,
there was a trend toward an improvement in the prob-
ability of EFS in patients with advanced disease phase
given early CsA compared to those receiving standard
CsA (42.1%, SE 11.3, versus 17.6%, SE 9.2, respec-
tively, P 5 .079, see also Figure 3).
Univariate analysis of the various patient-, donor-,
and transplantation-related factors potentially influ-
encing outcome (Table 3) showed that advanced dis-
ease phase (P 5 .0004), recipient male sex (P 5 .026),
donor age $35 years (P 5 .027), occurrence of grade
Table 4. Multivariate Analysis of Variables Influencing Event-
Free Survival, Relapse Rate, and 12-Month Treatment-Related
Mortality
HR 95% CI P Value
EFS
Disease phase
Advanced versus Early 3.18 (1.81-5.57) .0001
Acute GVHD grade
III-IV versus 0-II 2.69 (1.59-4.54) .0001
Donor age
>35 years
versus <35 years
2.19 (1.31-3.65) .003
Patient sex
F veruss M 0.56 (0.33-0.95) .032
RR
Disease phase
Advanced versus early 2.94 (1.43-6.03) .0032
Patient sex
F versus M 0.36 (0.16-0.84) .019
TRM No variable had any statistical impact
EFS indicates event-free survival; RR, relapse rate; TRM, treatment-
related mortality; RH, relative hazard; CI, confidence interval; F, female;
M, male; GVHD, graft-versus-host disease.
Figure 1. Probability of overall survival (OS), and of event-free survival
(EFS) in the whole cohort of patients.
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inferior EFS. All these factors maintained their prog-
nostic value in the multivariate Cox regression model
(Table 4).Figure 2. Probability of event-free survival (EFS) according to the
group of randomization; group 1 includes patients given CsA from day
–7; group 2 includes patients given CsA from day –1; HSCT, hematopoi-
etic stem cell transplantation.DISCUSSION
This prospective, randomized trial demonstrates
that early inception of CsA, even if associated with
higher blood levels of the drug at time of donor-cell in-
fusion (data not shown), failed to improve patient out-
comes. Although CsA, as a calcineurin inhibitor, has
the possibility of reducingT cell activation and the cyto-
kine storm associatedwith the tissue damage induced by
the conditioning regimen [9,27], the incidence of both
grade II-IV and grade III-IV aGVHDdid not differ be-
tween the 2 study groups. This lack of effect on the oc-
currence of aGVHD was associated with a comparable
incidence of TRM and of probabilities of EFS in the 2
groups. The discrepancy of our results with those previ-
ously reported [7,8], which offered the rationale for our
working hypothesis, may be explained by considering
different factors. In fact, although in those studies pa-
tientsweremainly adults affectedbyahomogeneousdis-
ease, namely Ph1 CML, we randomized pediatric
patients affected by different hematologicmalignancies,
mainly acute leukemia. Moreover, all our patients were
given ATG, which is known to induce in vivo T cell
depletion of the graft, as well as modulation of donor
T-lymphocyte function. Previously published reports
have shown that the use of ATG can reduce the inci-
dence of grade II-IV GVHD in patients transplanted
from an unrelated volunteer [28-30]. Thus, it cannot
be excluded that the administration of ATG in our pa-
tient population could have obscured the advantage ofan early start ofCsA.When our studywas started, histo-
compatibility was determined by serology for HLA-A
and -B antigens and by the high-resolution allelic tech-
nique for DRB1. In the second part of the study, high-
resolution (allelic level) typing for the HLA loci A, B,
C, DRB1, and DQB1 was performed to select donors.
Although the resulting information was not considered
for patient stratification in the randomization, the selec-
tion of the unrelated donors, using high-resolutionmo-
lecular typing for bothHLA class I and II loci, may have
contributed to reduce the risk of both aGVHD and
TRM, as previously reported [4,5,31], this factor also
being able to blunt the benefit derived from an earlier
administration of CsA. In any case, our results clearly
Figure 3. Probability of event-free survival (EFS) according to the group
of randomization in patients transplanted in advanced phase; group 1 in-
cludes patients given CsA from day –7; group 2 includes patients given
CsA from day –1; HSCT, hematopoietic stem cell transplantation.
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[7,8] must be validated in prospective randomized trials
before being considered sound enough to modify the
conventional approaches.When patients with advanced
disease phase were analyzed separately, we found a bet-
ter, althoughnot statistically significant, outcome if they
had receivedCsA fromday27.The reason for this find-
ing remainsunclear, althoughwedonot exclude thepos-
sibility that, if a larger number of patients with advanced
disease had been included in the randomized trial, the
value of ourworking hypothesismight bedemonstrated.
Analysis of the overall study group offered us the
opportunity to evaluate the impact of many patient-,
donor-, and transplantation-related variables on pa-
tient outcomes. These results can be of value in design-
ing specific risk-adapted treatment strategies based on
recipient characteristics [32].
Our data confirm that the outcome of patients
given HSCT from a UD has improved over time, the
51% 8-year EFS we observed in our cohort of children
with hematologic malignancies given an UD-HSCT
being comparable to the results reported in a cohort
of children with ALL transplanted in recent years
from an UD [4].
In keeping with Beatty et al. [33], we demonstrate
that the final outcome of patients with malignancies
transplanted from a 5/6matched donor does not signif-
icantly differ from that of patients given the allograft
from a 6/6 matched donor, thus proving that some de-
gree of HLA disparity can be tolerated, even more in
young patients who are transplanted fromUDs forma-
lignant disease, thus making transplantation an option
available to larger numbers of patients. We also con-
firm that the transplant success is strongly influenced
by the disease status at transplantation [6,34,35]. Ina previous paper, we showed that the main factor con-
ditioning a poor outcome of patients in need of an allo-
graft is relapse occurring while the search is still
ongoing, this being frequently seen for patients with
less frequent HLA haplotypes [34]. Thus, although
an optimal HLA matching in the donor/recipient pair
reduces the risk of TRM [4], our results suggest that
when a fully HLA-matched donor is not immediately
available, a subset of HLA disparities of little clinical
relevance can be accepted, without substantially lower-
ing survival [35]. Clearly, this consideration better
applies to patients at higher risk of relapse than to those
with a low probability of disease recurrence.
In keeping with a recent study by the National
Marrow Donor Program, in our study we did not
observe any adverse effect on EFS of donor and recip-
ient h-CMV positive serology [36].The timely diagno-
sis of h-CMV infection, with preemptive use of drugs,
such as ganciclovir, adopted in recent years [13], might
have contributed to prevent h-CMV disease and mor-
tality, abrogating any detrimental impact of this viral
infection on patient outcome.
We also confirm that donor age plays a significant
role in improving EFS, a finding already reported in
a study on a large number of patients by the National
Marrow Donor Program [36].
We found that both occurrence of grade III-IV
aGVHD and recipient male sex predicted an inferior
EFS. The detrimental effect played by occurrence of
severe GVHD resulted from an increased probability
of death due to transplant-related complications, as
suggested by the results of univariate analysis on
TRM. This unfavorable effect was not compensated
by any significant reduction of RR. The reason why
male patients had an inferior outcome compared to fe-
males is obscure, although, at least in ALL, males have
a greater probability of treatment failure even in the
context of conventional chemotherapy [37].
In conclusion, our data indicate that an early incep-
tion of CsA, although leading to higher blood levels of
the drug at time of infusion of donor cells, does not
reduce the risk of immune-mediated complications
and does not significantly improve patient outcome.ACKNOWLEDGMENTS
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